A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin™) in Combination With Bortezomib (PS-341, Velcade™) in Patients With Advanced Malignancy
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2013
At a glance
- Drugs Bortezomib (Primary) ; Oxaliplatin (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker
- 31 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 04 May 2007 Status changed from recruiting to completed
- 24 Aug 2005 New trial record.